Pharmaceuticals
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
CHICAGO, June 1, 2024 /PRNewswire/ -- On June 1st, 2024, Immunofoco Biotech, a company dedicated to developing cell therapy products for solid tumors, announced that the clinical research data for two of its products have been accepted for presentation at the 2024 American Society of Clinical Onc...
2024-06-02 03:00
2568
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress
in the construction of its alpaca-derived nanobody discovery platform,
ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully
replaced by alpaca IGH-VDJ genes in-situ.
2024-06-01 20:00
2115
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
* Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumors * A 40% overall response rate (ORR) and 100% disease control rate (DCR) were achieved in high-dose cohort (195 mg/day) *...
2024-06-01 20:00
4272
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Ratio of 0.48 5.6% Treatment Discontinuation of Ivonescimab due...
2024-06-01 19:10
4283
GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2
SHANGHAI, May 31, 2024 /PRNewswire/ -- Shanghai Grit Biotechnology Co., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) announced the establishment of a formal strategic partnership to leverage both parties' R&D capabilities in innovative T-cell therapy. The objective is to ...
2024-05-31 21:16
3246
Neurophet to participate BIO USA… exploring global partnership and business
* Neurophet's AI brain image analysis technology improves time and cost efficiency for drug development * Aims to create business opportunities with global pharmaceutical companies SEOUL, South Korea, May 31, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for...
2024-05-31 21:00
3525
OBiO Technology Officially Launched the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases
SHANGHAI, May 30, 2024 /PRNewswire/ -- On May 23, OBiO Technology, a world leading contract development and manufacturing organization for cell and gene therapy, officially launched the "Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases" ...
2024-05-30 21:00
2533
Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone
SHENZHEN, China, May 30, 2024 /PRNewswire/ -- On the 24th of May, Kexing Biopharm (688136.SH) announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently received a Notice of Approval for Drug Clinical Trials from the National Medical Products Administration, ap...
2024-05-30 17:09
2101
Full-Life Technologies Announces Clearance from FDA of IND Application for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
HEIDELBERG, Germany , May 29, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced it has received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) for clinical tr...
2024-05-30 08:00
1704
AVELOS THERAPEUTICS ANNOUNCES KRW 17 BILLION SERIES B FUNDING ROUND, SURPASSING KRW 30 BILLION TOTAL RAISED
Stassets Investment Leads Round with Major Contribution, Joined by LSK Investment and Shinhan Capital Investment Provides Crucial Resources for Company's Focus on Developing Small Molecule Synthetic New Drugs in Synthetic Lethality, DNA Damage Response, and Cell Cycle Sectors First-In-Class AD1...
2024-05-29 20:00
2876
Shanghai Customs introduces measures to facilitate cross-border trade
SHANGHAI, May 28, 2024 /PRNewswire/ -- A news report from english.shanghai.gov.cn: To better facilitate cross-border trade, Shanghai Customs has introduced 36 measures with a focus on enhancing the experience for businesses. Here are some highlights: 1. Streamlining Customs Procedures: These me...
2024-05-29 11:14
1917
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
KYOTO, Japan, May 28, 2024 /PRNewswire/ -- Rege Nephro CO., Ltd. (
https://www.regenephro.co.jp/en
2024-05-28 23:00
2523
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases
* Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. * Collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innova...
2024-05-28 19:00
2272
Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome
Highlights: * Statistically significant improvement from baseline assessed by both clinicians and caregivers in all four efficacy measures specifically designed for Pitt Hopkins syndrome (Wilcoxon signed rank test p<0.05) * Clinician and caregiver global efficacy measures showed a level of i...
2024-05-27 18:00
2600
Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response
- Lunit's ASCO 2024 presentations to highlight advances including HER2 ultra-low detection and AI-powered ICI response prediction models for NSCLC, demonstrating the impact of Lunit SCOPE suite on precision oncology SEOUL, South Korea, May 24, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leadin...
2024-05-24 22:07
6236
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting
SHANGHAI, May 24, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest progress of the Phase I/II clinical study of 9MW2821, a novel Nectin-4-targeting ADC for multiple advanced solid tumors, which will be reported as an oral pre...
2024-05-24 22:00
5988
Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024
SHANGHAI, May 24, 2024 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced latest clinical research results on GC203 (a novel non-viral vector gene-modif...
2024-05-24 20:00
4865
Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor
SHANGHAI, May 24, 2024 /PRNewswire/ -- Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been dosed in the Phase 1/2 trial of TSN1611 for the treatment of KRAS G12D mutant solid...
2024-05-24 16:33
2402
Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
* Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20ins status in plasma ctDNA. * Sunvozertinib could effectively clear EGFR exon20ins in plasma ctDNA, confirming its direct effect on EGFR pathway. * The resistance to sunvozertinib could be thro...
2024-05-24 16:32
2529
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates
SUZHOU, China and ROCKVILLE, Md., May 23, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that its four abstracts selected for presentations a...
2024-05-24 09:15
2591
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 318 media titles]
2026-01-29 15:06
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 318 media titles]
2026-02-02 10:00
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 284 media titles]
2026-02-01 19:35